COMBINATION DRUG SELECTION TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS

肌萎缩侧索硬化症的联合药物选择试验

• 批准号: 7725029
• 负责人: TAHSEEN MOZAFFAR
• 金额: $ 0.55万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7725029
• 关键词: Affect; Amyotrophic Lateral Sclerosis; Cell Death; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Disease; Drug Combinations; Drug Delivery Systems; Etiology; Free Radicals; Funding; Grant; Inflammation; Institution; Nerve Degeneration; Outcome; Pathway interactions; Pharmaceutical Preparations; Research; Research Design; Research Personnel; Resources; Screening procedure; Source; Testing; United States National Institutes of Health; concept; excitotoxicity; novel

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Multiple factors are responsible for disease causation in amyotrophic lateral sclerosis (ALS or Lou Gehrig s disease). Excess free radicals, energy mishandling, excitotoxicity, activation of cell death pathways and inflammation likely all contribute to disease causation and progression in ALS. Past clinical trials may have been negative in part because they tested single agents, usually influencing only one mechanism of cell death. Combinations of agents that affect different and multiple mechanisms of neurodegeneration may be necessary to reach meaningful outcomes in trials of ALS. This trial attempts two novel concepts in ALS: 1) a novel study design aimed at faster screening of medications that are effective; and 2) novel combination of drugs targeting different aspects of disease.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 肌萎缩侧索硬化症（ALS 或 Lou Gehrig 病）的致病因素有多种。过量的自由基、能量处理不当、兴奋性毒性、细胞死亡途径的激活和炎症都可能导致 ALS 的致病和进展。过去的临床试验可能呈阴性，部分原因是它们测试了单一药物，通常只影响一种细胞死亡机制。为了在 ALS 试验中达到有意义的结果，可能需要联合使用影响不同和多种神经退行性疾病机制的药物。该试验尝试了 ALS 中的两个新颖概念：1）旨在更快筛选有效药物的新颖研究设计； 2）针对疾病不同方面的新型药物组合。